Fact CheckerSign in

NCT04482894Active, not recruiting

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or High-Risk Myelodysplastic Syndrome: Randomized Phase II Study

Source: ClinicalTrials.gov · Last updated 4 May 2026

Brief summary (registry, in English)

The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
105 (estimated)
First submitted
8 Jul 2020
Start date
19 Aug 2020
Primary completion date
9 May 2027
Lead sponsor
University of Virginia
NCT number
NCT04482894

What you commit to

  • Study type: Interventional
  • Planned participants: 105
  • From 19 Aug 2020 to the primary completion date, 9 May 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • 1\. Participants must not have a diagnosis of Acute Promyelocytic Leukemia (APL)

Who the study is looking for

  • Ability to provide informed consent
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Any of the following:
    • Patients with a new diagnosis of AML, ALL, high risk myelodysplastic syndrome (MDS), or high risk chronic myelomonocytic leukemia (CMML) who are age 65 and older.
    • OR
    • Patients with relapsed AML, ALL, high risk MDS or high risk CMML, ages 18 and older.
    • OR
    • Patients with refractory AML, ALL, high risk MDS or high risk CMML, ages 18 and older.
    • Refractory AML/ALL will be defined as persistent leukemia despite two or more cycles of induction chemotherapy.
    • Refractory MDS will be defined according to the 2006 IWG response criteria Refractory CMML will be based on the assessment of the treating investigator.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Virginia
Coordinator of this site? Confirm its status		CharlottesvilleUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.